Get the Stockscreener App
445.12
3.56%
15.32
After Hours:
445.12
Alnylam Pharmaceuticals Inc stock is traded at $445.12, with a volume of 908.14K.
It is up +3.56% in the last 24 hours and down -3.95% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$429.80
Open:
$432.87
24h Volume:
908.14K
Relative Volume:
0.83
Market Cap:
$58.81B
Revenue:
$3.21B
Net Income/Loss:
$43.57M
P/E Ratio:
1,850.81
EPS:
0.2405
Net Cash Flow:
$221.36M
1W Performance:
-3.39%
1M Performance:
-3.95%
6M Performance:
+53.51%
1Y Performance:
+75.69%
1-Day Range:
$430.27
$447.69
1-Week Range:
$420.30
$467.73
52-Week Range:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 - Seeking Alpha
A Look at Alnylam Pharmaceuticals's Valuation Following Raised Sales Guidance on Vutrisiran Outperformance - simplywall.st
Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3 - MSN
Backdoor AI Beneficiary Yields 8.8%, Trades at 13% Discount - Investing.com
MoA Mid Cap Growth Fund's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback - Yahoo Finance
Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones? - simplywall.st
Small Interfering RNA (siRNA) Therapeutics Market 2025: - openPR.com
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
Alnylam's ATTR cardiomyopathy drug backed for NHS use - pharmaphorum
NICE Final Draft Guidance backs Alnylam’s Amvuttra - The Pharma Letter
Why Alnylam Pharmaceuticals Inc. (DUL) stock attracts wealthy investorsJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
Alnylam Pharmaceuticals Faces Weak Start with 6.56% Gap Down Amid Market Concerns - Markets Mojo
UK's drug-cost watchdog recommends Alnylam's heart disease drug - Reuters
High-Flying Biotech Stock Sets Up After 96% Pop; Profitability In Sight As Key Drug Sales Double - MSN
Is Alnylam Pharmaceuticals Inc. stock cheap at current valuationJuly 2025 Decliners & High Return Stock Watch Alerts - newser.com
Will Alnylam Pharmaceuticals Inc. (DUL) stock sustain bullish trend into 2025 - newser.com
Will Alnylam Pharmaceuticals Inc. stock deliver consistent dividendsTrade Analysis Report & Daily Growth Stock Investment Tips - newser.com
Is Alnylam Pharmaceuticals Inc. stock a defensive play in 2025Weekly Profit Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policiesWeekly Trading Summary & Real-Time Volume Analysis - newser.com
Regression analysis insights on Alnylam Pharmaceuticals Inc. performance2025 Top Gainers & Reliable Volume Spike Alerts - newser.com
Will Alnylam Pharmaceuticals Inc. continue its uptrendEarnings Miss & Smart Money Movement Tracker - newser.com
VP Fitzgerald Sells 12,128 ($5.5M) Of Alnylam Pharmaceuticals Inc [ALNY] - TradingView
[Form 4] ALNYLAM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peers2025 Top Decliners & Expert Approved Trade Ideas - newser.com
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stockQuarterly Profit Report & Reliable Intraday Trade Alerts - newser.com
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 11 - MarketScreener
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfolios2025 Price Targets & Smart Swing Trading Techniques - newser.com
What data driven models say about Alnylam Pharmaceuticals Inc.’s futureVolume Spike & Fast Moving Stock Watchlists - newser.com
How to recover losses in Alnylam Pharmaceuticals Inc. stockPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):